The estimated Net Worth of William Young is at least $4.53 Million dollars as of 6 May 2024. Mr. Young owns over 41,133 units of Nanostring Technologies Inc stock worth over $10,813 and over the last 21 years he sold NSTG stock worth over $4,276,650. In addition, he makes $241,462 as Independent Chairman of the Board at Nanostring Technologies Inc.
William has made over 16 trades of the Nanostring Technologies Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 41,133 units of NSTG stock worth $4,331 on 6 May 2024.
The largest trade he's ever made was exercising 52,500 units of Nanostring Technologies Inc stock on 25 May 2004 worth over $853,650. On average, William trades about 8,911 units every 187 days since 2004. As of 6 May 2024 he still owns at least 102,684 units of Nanostring Technologies Inc stock.
You can see the complete history of Mr. Young stock trades at the bottom of the page.
William D. Young serves as Independent Chairman of the Board of the Company. Mr. Young has served as the chairman of the board of directors since January 2010 and as a member of the audit committee from November 2011 to April 2019 and nominating and corporate governance committee since September 2013. Mr. Young was appointed as a member of the compensation committee in April 2019. Mr. Young is a Senior Advisor at Blackstone Life Sciences since November 2018, following Blackstone’s acquisition of Clarus Ventures. Prior to Blackstone he was a Venture Partner at Clarus Ventures, a health care and life sciences venture capital firm, which he joined in March 2010. Prior to joining Clarus Ventures, Mr. Young served from 1999 until June 2009 as chairman of the board of directors and Chief Executive Officer of Monogram Biosciences, a biotechnology company acquired by Laboratory Corporation of America in June 2009. From 1980 to 1999 Mr. Young was employed at Genentech, a biotechnology company acquired by Roche in March 2009, most recently as Chief Operating Officer from 1997 to 1999, where he was responsible for all Product Development, Manufacturing and Commercial functions. Mr. Young joined Genentech in 1980 as Director of Manufacturing and Process Sciences and became Vice President in 1983. Prior to joining Genentech, Mr. Young worked at Eli Lilly & Co. for 14 years and held various positions in production and process engineering, antibiotic process development and production management. Mr. Young is a member of the boards of directors of Vertex Pharmaceuticals and Theravance Biopharma where he is the lead independent director. Mr. Young retired from BioMarin Pharmaceutical’s board of directors in November 2015 and from Biogen Inc.’s board of directors in June 2014. Mr. Young received his M.B.A. from Indiana University and his B.S. in chemical engineering from Purdue University, and an honorary doctorate of engineering from Purdue University. Mr. Young was elected to The National Academy of
As the Independent Chairman of the Board of Nanostring Technologies Inc, the total compensation of William Young at Nanostring Technologies Inc is $241,462. There are 10 executives at Nanostring Technologies Inc getting paid more, with R. Bradley Gray having the highest compensation of $7,288,840.
William Young is 75, he's been the Independent Chairman of the Board of Nanostring Technologies Inc since 2010. There are no older and 18 younger executives at Nanostring Technologies Inc.
William's mailing address filed with the SEC is 530 FAIRVIEW AVENUE N, , SEATTLE, WA, 98109.
Over the last 11 years, insiders at Nanostring Technologies Inc have traded over $114,083,977 worth of Nanostring Technologies Inc stock and bought 981,722 units worth $9,126,410 . The most active insiders traders include Charles P Jr Waite, Lifesciences Ii, L.P.Clarus... und Nicholas Galakatos. On average, Nanostring Technologies Inc executives and independent directors trade stock every 16 days with the average trade being worth of $4,371. The most recent stock trade was executed by Joseph M Beechem on 6 May 2024, trading 147,853 units of NSTG stock currently worth $15,569.
nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali
Nanostring Technologies Inc executives and other stock owners filed with the SEC include: